persistent or recurrent disease
Showing 1 - 25 of >10,000
Ovarian Cancer, Oligometastatic Disease, Recurrent Ovary Cancer Trial (Stereotactic body radiotherapy)
Recruiting
- Ovarian Neoplasms
- +2 more
- Stereotactic body radiotherapy
-
Campobasso, CB, Italy
- +7 more
Sep 23, 2022
Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)
Not yet recruiting
- Recurrent Vulvar Cancer
- +3 more
- (no location specified)
Jun 12, 2023
Cervical Cancer Trial (Sacituzumab Govitecan)
Not yet recruiting
- Cervical Cancer
- Sacituzumab Govitecan
- (no location specified)
Apr 18, 2023
Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)
Not yet recruiting
- Persistent, Recurrent, or Metastatic Cervical Cancer
- GLS-010
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Apr 4, 2023
Atrial Fibrillation, Persistent, Atrial Fibrillation Recurrent Trial (Radio frequency ablation)
Not yet recruiting
- Atrial Fibrillation, Persistent
- Atrial Fibrillation Recurrent
- Radio frequency ablation
- (no location specified)
Oct 22, 2023
Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)
Not yet recruiting
- Cervical Cancer
- TQB2868 injection
- +4 more
-
Chongqing, Chongqing, China
- +1 more
Aug 17, 2023
METASTATIC CERVICAL CANCER Trial (QL1706, Placebo)
Recruiting
- METASTATIC CERVICAL CANCER
- QL1706
- +3 more
-
Chongqing, Chongqing, China
- +2 more
Nov 24, 2022
Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)
Not yet recruiting
- Ovarian Carcinoma
- Sacituzumab govitecan
-
New Haven, ConnecticutSmilow Cancer Hospital at Yale New Haven
Aug 31, 2023
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte
Active, not recruiting
- Adult Acute Myeloid Leukemia in Remission
- +12 more
- cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Cervical Cancer Trial in Hangzhou (Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin)
Recruiting
- Cervical Cancer
- Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Jul 12, 2022
Endometrial Cancer Recurrent Trial in Tainan (Crizotinib 250 MG)
Recruiting
- Endometrial Cancer Recurrent
- Crizotinib 250 MG
-
Tainan, TaiwanNational Cheng Kung University Hospital
Jun 6, 2022
Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)
Not yet recruiting
- Recurrent Endometrial Serous Adenocarcinoma
- Biospecimen Collection
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 12, 2023
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal
Recruiting
- Head and Neck Carcinoma of Unknown Primary
- +5 more
- External Beam Radiation Therapy
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Dec 1, 2022
Cervical Cancer Trial in Wuhan (Cadonilimab, Anlotinib)
Recruiting
- Cervical Cancer
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Apr 5, 2023
Endometrial Cancer, Recurrent Endometrial Cancer Trial in United States (LY3023414)
Completed
- Endometrial Cancer
- Recurrent Endometrial Cancer
-
Basking Ridge, New Jersey
- +5 more
Sep 13, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)
Completed
- Recurrent Cervical Carcinoma
- +5 more
- Chemotherapy plus apatinib
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)
Not yet recruiting
- Uterine Cervical Neoplasms
- +5 more
- Cadonilimab
- Nab paclitaxel
- (no location specified)
Apr 9, 2023
Endometrial Cancer Trial in Birmingham, Saint Louis, Oklahoma City (Bevacizumab, Atezolizumab)
Active, not recruiting
- Endometrial Cancer
-
Birmingham, Alabama
- +2 more
Nov 21, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1
Completed
- Recurrent Cervical Carcinoma
- +4 more
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Persistent or Recurrent Cutaneous T-Cell Lymphoma Trial in Australia, Puerto Rico, United States (E7777 9 mcg/kg)
Completed
- Persistent or Recurrent Cutaneous T-Cell Lymphoma
- E7777 9 mcg/kg
-
Birmingham, Alabama
- +21 more
Dec 5, 2022
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and
Not yet recruiting
- Recurrent Endometrial Carcinoma
- Recurrent Ovarian Carcinoma
- Biopsy
- +5 more
- (no location specified)
Sep 29, 2022